CAS: 479-18-5; 7-(2,3-Dihydroxypropyl)-1,3-Dimethyl-1H-Purine-2,6(3H,7H)-Dione

上下游产品

CAS号519-37-9 7-(2-羟基乙基)茶碱 | CAS号96474-41-8 2-(1,3-dimethyl... | CAS号42891-30-5 1H-Purine-2,6-d... | CAS号62637-09-6 7-(2,3-dihydrox... | CAS号5614-53-9 多索茶碱杂质01

Dyphylline 2',3'-Di-P-Chlorobenzoate 以 甲醇 作为反应溶剂,化学反应生成 二羟丙茶碱
参考文献:茶碱前药:兔血浆水解和茶碱释放
标题:茶碱前药:兔血浆水解和茶碱释放
摘要:茶碱[7-(2,3-二羟丙基)茶碱]的前药酯水解在人和兔血浆中均遵循一级动力学.速率常数通过初始转化率的线性回归分析估算,初始转化率是在不同的初始前药浓度下确定的.在兔血浆中,从前药中释放的茶碱比人血浆快1.3至13倍.但是,在兔子和人血浆中,药物的相对释放速率(不稳定性顺序)遵循相同的模式.静脉内给予2',3'-双戊二酸茶碱后,兔血浆中茶碱的浓度略有增加.兔体内前药的口服给药大大维持了血浆茶碱浓度.
DOI:10.1002/jps.2600770203

专利信息

专利号:US-8957230-B2
优先权日:2011-06-30
标 题 :Synthesis of cleistanthin A and derivatives thereof
发明人：MULIK NILESH SHRIDHAR; PANGHAVANE KAILASH DATTATRAYA
权利人:MULIK NILESH SHRIDHAR; PANGHAVANE KAILASH DATTATRAYA
摘要:The present invention provides a method for preparing Cleistanthin A, a diphyllin glycoside, derivatives thereof and intermediates thereto. In particular the present invention provides in one of the aspect a method for synthesis of compound of formula D a key intermediate of diphyllin, which can be carried out in a shorter duration and at an ordinary temperature.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-5969170-A
优先权日:1992-04-03
标 题:High activity ruthenium and osmium metal carbene complexes for olefin metathesis reactions
发明人：GRUBBS ROBERT H; NGUYEN SONBINH T; JOHNSON LYNDA K
权利人:CALIFORNIA INST OF TECHN
摘要:Disclosed are ruthenium and osmium carbene compounds which are stable in the presence of a variety of functional groups and which can be used to catalyze olefin metathesis reactions on strained and unstrained cyclic and acyclic olefins. Specifically, the present invention relates to carbene compounds of the formula ##STR1## wherein: M is Os or Ru; R and R 1 are independently selected from hydrogen and substituent groups C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, C 1 -C 20 alkyl, aryl, C 1 -C 20 carboxylate, C 2 -C 20 alkoxy, C 2 -C 20 alkenyloxy, C 2 -C 20 alkynyloxy, aryloxy, C 2 -C 20 alkoxycarbonyl, C 1 -C 20 alkylthio, C 1 -C 20 alkylsulfonyl or C 1 -C 20 alkylsulfinyl; each substituent group optionally substituted with C 1 -C 5 alkyl, a halogen, C 1 -C 5 alkoxy or with a phenyl group optionally substituted with a halogen, C 1 -C 5 alkyl or C 1 -C 5 alkoxy; X and X 1 are independently selected from any anionic ligand; and L and L 1 are each trialkyl phosphine ligands where at least one of the alkyl groups on the phosphine is a secondary alkyl or a cycloalkyl. A broad array of metathesis reactions are enabled including ring-opening metathesis polymerization of cyclic olefins, ring closing metathesis of acyclic dienes, cross metathesis involving at least one acyclic or unstrained cyclic olefin, depolymerization of unsaturated polymers and synthesis of telechelic polymers.

专利号:WO-2009003085-A1
优先权日:2007-06-27
标 题:Process for the manufacture of hydrofluoroolefins via metathesis
发明人：ELSHEIKH MAHER Y; BONNET PHILIPPE
权利人:ARKEMA INC; ELSHEIKH MAHER Y; BONNET PHILIPPE
摘要:The present invention is direct toward a process for the synthesis of hydrofluoroolefins (HFO). The process is based on an olefin metathesis reaction of a hydrofluoroolefin in the presence of metathesis catalyst whereby the carbon-carbon double bonds in the olefins (alkenes) are rearranged to form three carbon hydrofluoroolefins of the formula CFa H 3-a C Fb H 1-b = C Fd H 2-d where a, b and d are as defined in the application.

专利号:WO-2006008175-A1
优先权日:2004-07-23
标 题 :Rapid flame synthesis of doped zno nanorods with controlled aspect ration
发明人：HEIGHT MURRAY J; MAEDLER LUTZ; PRATSINIS SOTIRIS
权利人:ETH ZUERICH; HEIGHT MURRAY J; MAEDLER LUTZ; PRATSINIS SOTIRIS
摘要:Described is a flame spray pyrolysis (FSP) method for the production of nanorods wherein at least one dopant metal precursor is added to a precursor solution of the predominant metal in amounts of at most 15 atom-% referred to the predominant metal, said dopant having an higher valency than the predominant metal, and wherein the crystal lattice of the pure metal oxide formed by FSP is in a hexagonal closed package. In preferred embodiments, the coordination number of the dopant atoms is higher than the coordination number of the predominant metal atoms and the dopant atoms and/or ions and the predominant metal atoms/ions have sizes varying by less than 20 atom-%.

专利号:US-8017776-B2
优先权日:2003-07-15
标题 :Methods for synthesis of acyloxyalkyl compounds
发明人：BHAT LAXMINARAYAN; GALLOP MARK A
权利人:XENOPORT INC
摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.